ALGN:NSD-Align Technology Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 172.22

Change

+0.81 (+0.47)%

Market Cap

USD 11.30B

Volume

1.61M

Analyst Target

USD 325.93
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package to treat adults and teens from mild to severe malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; as well as Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. The Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing (CAD/CAM) software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. The company was incorporated in 1997

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-21 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-14.42 (-2.99%)

USD 161.79B
COO The Cooper Companies, Inc

-0.81 (-1.02%)

USD 15.49B
HOLX Hologic Inc

-0.62 (-1.08%)

USD 13.84B
RGEN Repligen Corporation

+1.64 (+1.26%)

USD 7.49B
MMSI Merit Medical Systems Inc

-1.29 (-1.42%)

USD 6.12B
ICUI ICU Medical Inc

-1.95 (-1.41%)

USD 3.43B
XRAY Dentsply Sirona Inc

-0.01 (-0.08%)

USD 2.70B
LMAT LeMaitre Vascular Inc

-1.56 (-1.81%)

USD 1.93B
ATRC AtriCure Inc

-0.27 (-0.84%)

USD 1.70B
AZTA Azenta Inc

-0.22 (-0.87%)

USD 1.43B

ETFs Containing ALGN

UGCE 3.86 % 0.00 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 1.94 % 0.35 %

-1.08 (0.00%)

USD 0.16B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 4.72B
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.40% 47% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.40% 47% F 43% F
Trailing 12 Months  
Capital Gain -42.75% 36% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.75% 36% F 26% F
Trailing 5 Years  
Capital Gain -9.37% 52% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.37% 52% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 2.09% 60% D- 48% F
Dividend Return 2.09% 60% D- 43% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 58.99% 45% F 31% F
Risk Adjusted Return 3.54% 55% F 40% F
Market Capitalization 11.30B 92% A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.